2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Multiple Myeloma
9
Lymphoma, Follicular
4
Recurrence
3
Lymphoma, B-Cell
3
Neoplasms, Plasma Cell
2
Burkitt Lymphoma
2
Spondylolisthesis
1
Spinal Stenosis
1
Spinal Cord Neoplasms
1
Smoldering Multiple Myeloma
1
Neoplasms
1
Neoplasm, Residual
1
Meningeal Carcinomatosis
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma
1
Lymphedema
1
Leukemia, Promyelocytic, Acute
1
Leukemia, Myeloid, Acute
1
Intervertebral Disc Displacement
1
Intervertebral Disc Degeneration
1
Hodgkin Disease
1
Failed Back Surgery Syndrome
1
Disease Progression
1
Disease
1
Breast Neoplasms
1
Bone Neoplasms
1
Interventions
Lenalidomide
4
Gemcitabine
4
Dexamethasone
4
Cyclophosphamide
4
Bortezomib
4
Nivolumab
3
Cisplatin
3
Carboplatin
3
vandetanib
2
tumor necrosis factor-alpha, CNGRC fusion protein, human
2
pomalidomide
2
pembrolizumab
2
liposomal doxorubicin
2
fludarabine
2
durvalumab
2
capivasertib
2
Radiosurgery
2
Paclitaxel
2
Doxorubicin
2
Bevacizumab
2
Anthropogenic Effects
2
venetoclax
1
umbralisib
1
ublituximab
1
tremelimumab
1
tivozanib
1
ricolinostat
1
regorafenib
1
pazopanib
1
niraparib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Disease Progression
×
Transplantation, Autologous
×
Clear all
NCT02043847
2024-11-13
BMT-03
University of Illinois at Chicago
Phase 1
Completed
12 enrolled
12 charts